平安好醫生(01833.HK)與優時比製藥簽約 建藥醫險融合發展新模式
平安好醫生(01833.HK)公布,與優時比製藥正式簽署戰略合作協議,雙方將在基於數字平台的創新患者服務、智慧醫療以及大數據和人工智能應用等方面展開合作,探索對患者有價值、對行業有助力的信息技術應用和醫療健康服務創新模式,為用戶提供有溫度的醫療健康服務。
雙方將從專科專病入手,逐步拓展至更多疾病領域,合作的第一步以類風濕性關節炎產品為基礎推出定製化藥費險,隨著合作的深化,雙方將不斷探索醫、藥、險全面融合,並將拓展至更多疾病領域的保險產品和創新支付。(ek/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.